18:25 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Synchronous signaling

As researchers explore next-generation CARs in cancer, one strategy is to tinker with the receptors’ modular components. A Science Signaling paper suggests that altering the number of ITAM repeats in the intracellular domains of a...
17:46 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells with six ITAMS could have greater activity towards cancer cells than CAR T cells with the standard three ITAMS. The cells are generated by duplicating the CD3ζ (CD3z; CD247)...
18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
20:41 , Sep 8, 2017 |  BC Week In Review  |  Company News

J&J ends deal for Macrogenics' duvortuxizumab

MacroGenics Inc. (NASDAQ:MGNX) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) terminated its license to duvortuxizumab (MGD011), a bispecific antibody against CD19 and CD3 . MacroGenics said the termination will not affect...
22:57 , Jun 29, 2017 |  BC Innovations  |  Product R&D

Drop the MIC

Two start-ups have joined the wave of companies harnessing NK cell biology to generate new immunotherapies for cancer by focusing on the relatively unexplored ligands for the NK cell receptor NKG2D . Having laid low...
19:46 , Jun 12, 2017 |  BC Extra  |  Financial News

Carma raises venture funding

Carma Therapeutics Inc. (Philadelphia, Pa.) said it raised an undisclosed amount in an "initial" round of financing co-led by AbbVie Ventures and HealthCap. Grazia Equity and IP Group plc (LSE:IPO) also participated. The company, which...
19:45 , Jun 12, 2017 |  BC Extra  |  Company News

Celgene gets options to Dragonfly's NK receptor antibodies

Dragonfly Therapeutics Inc. (Cambridge, Mass.) and Celgene Corp. (NASDAQ:CELG) began a five-year collaboration to discover, develop and commercialize candidates to treat hematologic malignancies based on Dragonfly’s TriNKET (Trispecific NK cell Engager Therapies) platform. Celgene will...
13:17 , May 18, 2017 |  BC Innovations  |  Emerging Company Profile

Spreading Carma

Carma Therapeutics LLC is subverting macrophages’ tumor-promoting role by engineering in chimeric antigen receptors (CARs) to turn the phagocytic cells into agents that suppress the growth of solid tumors. The company is a translational play...
21:24 , May 11, 2017 |  BC Innovations  |  Translation in Brief

Going universal

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) is going allogeneic and ditching antigen specificity to broaden the reach of its chimeric antigen receptor (CAR)-expressing T cells. By suppressing endogenous T cell receptor (TCR) expression and using NK cell...